亿帆医药(002019) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥1,020,118,230.77, a decrease of 23.39% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥77,622,349.17, down 59.76% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥65,726,125.51, reflecting a decline of 64.38% compared to the previous year[3]. - The basic earnings per share for the period was ¥0.06, a decrease of 62.50% year-on-year[3]. - Total operating revenue for Q3 2021 was ¥3,397,522,083.07, a decrease of 17.9% compared to ¥4,142,231,771.86 in the same period last year[25]. - Net profit for Q3 2021 was ¥242,333,816.18, down 72.6% from ¥884,551,785.31 in Q3 2020[26]. - Earnings per share (EPS) for Q3 2021 was ¥0.24, compared to ¥0.74 in the same quarter last year[27]. - The company's total comprehensive income for Q3 2021 was ¥204,241,290.93, significantly lower than ¥870,206,230.11 in Q3 2020[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥11,977,316,407.73, an increase of 2.92% from the end of the previous year[4]. - Total liabilities amounted to ¥11,977,316,407.73, an increase from ¥11,637,239,651.30 year-over-year[24]. - Total equity reached ¥8,878,539,248.40, up from ¥8,730,227,226.07 in the previous year[24]. - The total assets increased to ¥11,708,097,760.68 from ¥11,637,239,651.30, reflecting a growth of approximately 0.61%[30]. - The total liabilities increased, with short-term borrowings remaining at ¥1,193,086,922.56, unchanged from the previous period[30]. - Total liabilities amounted to CNY 2,907,012,425.23, a decrease of CNY 83,837,192.14 from the previous quarter[31]. - Current liabilities totaled CNY 2,128,945,704.81, reflecting a decrease of CNY 13,481,600.17 compared to the previous quarter[31]. - Non-current liabilities decreased to CNY 778,066,720.42, down by CNY 70,355,591.97 from the previous quarter[31]. Cash Flow - The company reported a net cash flow from operating activities of ¥327,901,225.80, a decrease of 69.88% year-to-date[3]. - Cash flow from operating activities decreased by 69.88% to ¥327,901,225.80, mainly due to reduced cash inflow from sales of goods[10]. - Operating cash flow for the period was ¥327,901,225.80, a decrease of 69.9% compared to ¥1,088,478,560.76 in the previous period[28]. - Cash inflow from investment activities was ¥1,240,000,000.00, up from ¥1,015,000,000.00 in the previous period, while cash outflow was ¥1,921,724,244.94, compared to ¥1,604,391,097.40 previously, resulting in a net cash flow from investment activities of -¥659,887,548.59[29]. - Total cash inflow from financing activities was ¥2,248,099,792.61, an increase from ¥1,942,209,194.94 in the previous period, while cash outflow was ¥2,063,991,064.16, slightly down from ¥2,099,354,004.62, leading to a net cash flow from financing activities of ¥184,108,728.45[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 53,388[11]. - The largest shareholder, Cheng Xianfeng, holds 40.23% of the shares, amounting to 496,526,307 shares[11]. - The company plans to repurchase shares with a budget between RMB 100 million and RMB 150 million, with a maximum repurchase price of RMB 21.88 per share[20]. - As of September 30, 2021, the company had repurchased a total of 4,826,442 shares, accounting for 0.39% of the total share capital, with a total expenditure of approximately RMB 80.69 million[21]. Operational Highlights - Sales expenses increased by 30.33% to ¥607,223,802.44 compared to the same period last year, primarily due to increased promotion of proprietary and imported pharmaceutical products[9]. - Investment income decreased by 112.89% to -¥8,652,029.04, mainly due to increased investment losses from joint ventures[9]. - Operating profit dropped by 74.21% to ¥277,135,721.74, attributed to a significant decline in the price of vitamin B5 in the raw material drug sector[9]. - Net profit attributable to shareholders decreased by 68.09% to ¥290,763,438.71, driven by lower gross profit and increased sales expenses[9]. - Research and development expenses for Q3 2021 were ¥132,958,645.93, a decrease of 11% from ¥149,383,056.45 in Q3 2020[26]. Regulatory and Compliance - The company has implemented a stock incentive plan, with the second unlock period for restricted stock completed as of June 24, 2021[15]. - The company received a registration acceptance notice for the overseas production of cross-linked sodium hyaluronate injection (brand name: Hyruan ONE®) on July 21, 2021[17]. - The company’s subsidiary received a registration acceptance notice for chlorpromazine injection on August 2, 2021[17]. - Shanghai Yiyi obtained approval for a Phase II clinical trial for the product F-652 for the indication of acute liver failure on September 7, 2021[18]. - A commercialization cooperation agreement was signed on August 26, 2021, granting exclusive licensing of F-627's intellectual property rights in China to Zhengda Tianqing Pharmaceutical Group[19]. Future Outlook - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[29].